BioSpace News Archive

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it will host an Investor Day on Wednesday, May 29, 2024, at 1:00 p.m. E.T. until approximately 4:30 p.m. ET at the New York Stock Exchange in New York City.

Global biotechnology leader CSL and Arcturus Therapeutics announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying COVID-19 vaccine and the world’s first approved sa-mRNA COVID-19 vaccine.

GRI Bio, Inc. today presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

Danimer Scientific, Inc. announced today that Stephen E. Croskrey has informed the Board of Directors that he will retire as Chief Executive Officer not later than the end of this calendar year.

“Currently More Than 10 Therapies Are Under Clinical Trials, Majority Of Therapies Evaluated For Multiple Myeloma”

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) (“Kiora” or the “Company”), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand.

Intercept Pharmaceuticals, Inc. is presenting two new sub-analyses from its Phase 3 POISE study in primary biliary cholangitis (PBC), at Digestive Disease Week® (DDW) 2024 in Washington, D.C.

GigaGen Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its anti-CTLA-4 oncology drug, GIGA-564, for the treatment of metastatic or locally advanced solid tumors.

APRINOIA Therapeutics today announced that on May 8, 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to APN-1607 (florzolotau), a Positron Emission Tomography (PET) tracer for imaging tau protein in patients with suspected progressive supranuclear palsy (PSP).